WHO ICTRP trial
Investigation of alpha-lipoic acid supplementation in patients with…
ACTRN12613000982718 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12613000982718 |
|---|---|
| Public title | Investigation of alpha-lipoic acid supplementation in patients with schizophrenia |
| Scientific title | Investigation of alpha-lipoic acid supplementation on oxidative stress parameters in patients with schizophrenia |
| Primary sponsor | University of Belgrade, Faculty of Pharmacy |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not Applicable |
| Countries | Serbia and Montenegro |
| Conditions | Schizophrenia;Metabolic sindrome;Cardiovascular disease; Schizophrenia Metabolic sindrome Cardiovascular disease;Mental Health - Schizophrenia |
| Interventions | This study will evaluate the effect of alpha lipoic acid (LA) in patients with schizophrenia treated with antipsychotics drugs. In this open label, interventional study we will investigate LA effects (capsule with 500 mg LA, once day 30 min… |
| Registration date | Mar 9, 2013 |
| Target size | 80 |
| Secondary IDs | Nil |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: